MEDIFAST INC Common Stock (MED)

Medifast (MED) Q4 2025 Earnings Call Transcript

Wellness company Medifast (NYSE:MED) reported Q4 CY2025 results exceeding the market’s revenue expectations, but sales fell by 36.9% year on year to $75.1 million. On the other hand, next quarter’s revenue guidance of $72.5 million was less impressive, coming in 15.2% below analysts’ estimates. Its GAAP loss of $1.65 per share was significantly below analysts’ consensus estimates.

Wellness company Medifast (NYSE:MED) will be reporting results this Tuesday after the bell. Here’s what to expect.

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.

Over the past six months, Medifast’s stock price fell to $11.62. Shareholders have lost 18.9% of their capital, which is disappointing considering the S&P 500 has climbed by 11.3%. This might have investors contemplating their next move.

Consumer staples stocks are solid insurance policies in frothy markets ripe for corrections. But they’re also double-edged swords as they often lag in booming conditions, and this pattern has persisted recently. Over the past six months, the industry has recorded a loss of 5.8%, a far cry from the S&P 500’s 12.7% ascent.

As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the personal care industry, including Medifast (NYSE:MED) and its peers.

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

Medifast’s third quarter results met Wall Street’s revenue expectations, but the market responded negatively as sales continued to decline sharply year-over-year. Management attributed these results to ongoing headwinds in the weight loss industry—most notably, increased competition from GLP-1 medications and declines in the number of active earning coaches. CEO Dan Chard highlighted that the company’s evolving science-backed approach to metabolic health aims to differentiate Medifast in a changing landscape. Chard pointed to coach-led support and recent clinical studies as key elements, while also acknowledging the need for further progress in reversing declining sales.

Wellness company Medifast (NYSE:MED) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 36.2% year on year to $89.41 million. On the other hand, next quarter’s revenue guidance of $72.5 million was less impressive, coming in 1.8% below analysts’ estimates. Its GAAP loss of $0.21 per share was 41.7% above analysts’ consensus estimates.

Wellness company Medifast (NYSE:MED) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 36.2% year on year to $89.41 million. On the other hand, next quarter’s revenue guidance of $72.5 million was less impressive, coming in 1.8% below analysts’ estimates. Its GAAP loss of $0.21 per share was 41.7% above analysts’ consensus estimates.

Wellness company Medifast (NYSE:MED) will be announcing earnings results this Monday after market hours. Here’s what to look for.

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.

Medifast has been treading water for the past six months, recording a small loss of 0.7% while holding steady at $13.57. The stock also fell short of the S&P 500’s 18.4% gain during that period.

Medifast currently trades at $13.57 per share and has shown little upside over the past six months, posting a small loss of 0.7%. The stock also fell short of the S&P 500’s 18.4% gain during that period.

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.